Search

Displaying results 2351 - 2360 of 4591 in total
  1. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

  2. Drug

    α-Methylacetylfentanyl

    go.drugbank.com/drugs/DB01532
    ExperimentalIllicit

    It was categorized under the Schedule I in the US and it was illegally sold in early 1980. α-Methylacetylfentanyl synthesis process is very similar to α-methylfentanyl with the substitution of the acetic

  3. Drug

    Cetalkonium

    go.drugbank.com/drugs/DB11583
    ApprovedWithdrawn

    [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]

  4. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.

  5. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  6. Drug

    Teniposide

    go.drugbank.com/drugs/DB00444
    ApprovedInvestigational

    Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

  7. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis.

  8. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    [L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425]

  9. Drug

    Boric acid

    go.drugbank.com/drugs/DB11326
    ApprovedInvestigational

    Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and

  10. Drug

    Hydroxyproline

    go.drugbank.com/drugs/DB08847
    Approved

    Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds.